Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | PKM | P14618 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | KRAS | P01116 | 1/20 | 0.60 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.59 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977480 | 0.84 | MAPT (1.00) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL4400320 | 0.84 | MAPT (1.00) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL31088338 | 0.84 | NPC1 (0.70) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL9227613 | 0.84 | NPC1 (0.70) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL9227606 | 0.84 | NPC1 (0.70) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL4041794 | 0.83 | NPC1 (0.74) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL4042548 | 0.83 | NPC1 (0.74) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL1604280 | 0.83 | MAPT (0.79) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL31436352 | 0.83 | MAPT (0.79) | NPC1PKMRAB9AKDM4EMAPT | |
| SCHEMBL6169751 | 0.83 | NPC1 (0.68) | NPC1PKMRAB9AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | NPC1 1909/4885PKM 2223/4885RAB9A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.